Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

evidence generation

- PMLiVE

NICE metrics flawed and should not be used, says EU study

ECHOUTCOME criticises used of quality adjusted life years in HTAs

- PMLiVE

Pharma ‘influencing Polish drug market’

Leads to recommendations for expensive and ineffective medicines says study

- PMLiVE

Patient access schemes likely to remain under VBP, says NICE

New and existing schemes expected to have place within UK’s new pricing environment

A new dogma in HTA assessment

New communication routes to HTA agencies are needed to ensure that these organisations can advise on clinical trial design

- PMLiVE

The bigger picture in medicine value

By focusing on cost are we obscuring the true value of medicines?

- PMLiVE

Demonstrating value and improving access

In today’s dynamic healthcare market, it’s all about how we can demonstrate value and improve access – it is the art of effective communication and education that will enable success

- PMLiVE

Embracing the new paradigm in pharma market access

Pharma needs to change its image from being drug producers to healthcare provider partners

- PMLiVE

Understanding the interconnected HTA universe

Pharma needs to identify and understand how individual HTA agencies are connected, viewing them as a network

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links